Mimedx (MDXG) Research & Development (2011 - 2026)

Mimedx (MDXG) has 16 years of Research & Development data on file, last reported at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 24.4% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $15.9 million (up 23.99% YoY), and the FY2025 full-year result was $15.1 million, up 22.33% from the prior year.
• Research & Development fell to $4.1 million in Q1 2026, from $4.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2022 to a low of -$4.7 million in Q4 2022.
• A 5-year average of $3.3 million and a median of $3.5 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development plunged 66.6% in 2022 and jumped 151.46% in 2023, its largest moves.
• Tracing MDXG's Research & Development over 5 years: stood at -$4.7 million in 2022, then jumped by 151.46% to $2.4 million in 2023, then surged by 46.77% to $3.6 million in 2024, then jumped by 33.32% to $4.8 million in 2025, then dropped by 13.04% to $4.1 million in 2026.
• Business Quant data shows MDXG's Research & Development at $4.1 million in Q1 2026, $4.8 million in Q4 2025, and $3.7 million in Q3 2025.